Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. ESMO Videos
  3. Breast Cancer Videos

Stereotactic body radiation therapy+/- durvalumab +/- oleclumab combined with neo-adjuvant chemotherapy for early-stage, high risk ER+/HER2 - breast cancer

Breaking Science in Breast Cancer Video Series

Login to get immediate access to this content.

Login

Speaker: Alex De Caluwe, Belgium

Abstracts discussed:

  • LBA10 - Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC): Watch the presentation from ESMO 2024 now

The speakers and studies featured in this video series were selected independently by ESMO.

Published October 2024

Related Videos

Screenshot Barbara PISTILLI
Screenshot Marleen KOK
Screenshot Helene RUNDQVIST
Screenshot Ichiro KINOSHITA

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.